Noninterventional cohort study shows FLT3 mutation status affects outcomes in acute myeloid leukemia, suggesting earlier retesting may improve treatment planning.
Dynamic changes in FLT3 mutation status were observed during these patients' disease course. FLT3pos status at baseline, but not at first occurrence, was associated with improved outcomes; other confounders should be considered. Timelier FLT3 mutation retesting may aid in personalizing treatment. Graphical abstract available for this article.
No takes yet. Share an insight, caveat, or question.
Papayannidis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: